Windtree Therapeutics Inc (NASDAQ:WINT) has completed enrollment in its phase 2 study of istaroxime in early cardiogenic shock caused by heart failure.

• The study enrolled 60 patients with severe heart failure and systolic blood pressure (SBP) between 75 and 90 mmHg. 
• The study drug was administered over 24 hours. The primary endpoint is the SBP profile over the first 6 hours after initiating the infusion. 
• Secondary endpoints will include various assessments of blood pressure changes over 24 hours and measures associated with safety and tolerability. 
• All patients will complete a 30-day follow-up before database lock and generation of topline data.
• Topline data is expected in April.
• Cardiogenic shock is a condition that occurs when the heart is failing significantly and cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs. 
• Istaroxime is a first-in-class, dual mechanism therapy designed to improve systolic and diastolic cardiac function.
• Price Action: WINT shares are up 1.02% at $0.95 during the market session on the last check Tuesday.